Detail akcie Alnylam Pharm online

Business Summary: Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Alnylam Pharmaceuticals, Inc. revenues increased 96% to $1.17B. Net income totaled $206M vs. loss of $18.3M. Revenues reflect AMVUTTRA segment increase from $310M to $889.9M, Roche segment increase from $17.1M to $35.6M, United States segment increase from $271.4M to $778.8M, Rest of World segment increase of 80% to $91.8M.